Erratum: Intravenous ketamine for adolescents with treatment-resistant depression: An Open-Label Study, by Cullen KR, Amatya P, Roback MG, Albott CS, Westlund Schreiner M, Ren Y, Eberly LE, Carstedt P, Samikoglu A, Gunlicks-Stoessel M, Reigstad K, Horek N, Tye S, Lim KO, Klimes-Dougan B. (J Child Adolesc Psychopharmacol (2018) 28:7 (437-444) DOI: 10.1089/cap.2018.0030)

K. R. Cullen, P. Amatya, M. G. Roback, C. S. Albott, M. Westlund Schreiner, Y. Ren, L. E. Eberly, P. Carstedt, A. Samikoglu, M. Gunlicks-Stoessel, K. Reigstad, N. Horek, Susannah J Tye, K. O. Lim, B. Klimes-Dougan

Research output: Contribution to journalComment/debate

Abstract

In the September 2018 issue of Journal of Child and Adolescent Psychopharmacology (vol. 28, no. 7, pp. 437-444), the article "Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study," by Dr. Kathryn R. Cullen et al., was missing the financial support information as follows: This research was supported by the National Institutes of Health's National Center for Advancing Translational Sciences (UL1TR002494), the Biotechnology Research Center (P41 EB015 894), the NINDS Institutional Center Core Grants to Support Neuroscience Research (P30 NS076408), the High Performance Connectome Upgrade for Human 3TMR Scanner (1S10OD017974-01), and the University Foundation, Amplatz Scholarship. The online version of the article has been corrected to reflect this additional information. The authors wish to apologize for the omission.

Original languageEnglish (US)
Number of pages1
JournalJournal of Child and Adolescent Psychopharmacology
Volume29
Issue number1
DOIs
StatePublished - Sep 1 2018

Fingerprint

Treatment-Resistant Depressive Disorder
Ketamine
Connectome
Research
National Institute of Neurological Disorders and Stroke
Financial Support
Psychopharmacology
Organized Financing
National Institutes of Health (U.S.)
Biotechnology
Neurosciences
S-Lim

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Erratum : Intravenous ketamine for adolescents with treatment-resistant depression: An Open-Label Study, by Cullen KR, Amatya P, Roback MG, Albott CS, Westlund Schreiner M, Ren Y, Eberly LE, Carstedt P, Samikoglu A, Gunlicks-Stoessel M, Reigstad K, Horek N, Tye S, Lim KO, Klimes-Dougan B. (J Child Adolesc Psychopharmacol (2018) 28:7 (437-444) DOI: 10.1089/cap.2018.0030). / Cullen, K. R.; Amatya, P.; Roback, M. G.; Albott, C. S.; Westlund Schreiner, M.; Ren, Y.; Eberly, L. E.; Carstedt, P.; Samikoglu, A.; Gunlicks-Stoessel, M.; Reigstad, K.; Horek, N.; Tye, Susannah J; Lim, K. O.; Klimes-Dougan, B.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 29, No. 1, 01.09.2018.

Research output: Contribution to journalComment/debate

@article{470342817bed4563a398141fa5d2873e,
title = "Erratum: Intravenous ketamine for adolescents with treatment-resistant depression: An Open-Label Study, by Cullen KR, Amatya P, Roback MG, Albott CS, Westlund Schreiner M, Ren Y, Eberly LE, Carstedt P, Samikoglu A, Gunlicks-Stoessel M, Reigstad K, Horek N, Tye S, Lim KO, Klimes-Dougan B. (J Child Adolesc Psychopharmacol (2018) 28:7 (437-444) DOI: 10.1089/cap.2018.0030)",
abstract = "In the September 2018 issue of Journal of Child and Adolescent Psychopharmacology (vol. 28, no. 7, pp. 437-444), the article {"}Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study,{"} by Dr. Kathryn R. Cullen et al., was missing the financial support information as follows: This research was supported by the National Institutes of Health's National Center for Advancing Translational Sciences (UL1TR002494), the Biotechnology Research Center (P41 EB015 894), the NINDS Institutional Center Core Grants to Support Neuroscience Research (P30 NS076408), the High Performance Connectome Upgrade for Human 3TMR Scanner (1S10OD017974-01), and the University Foundation, Amplatz Scholarship. The online version of the article has been corrected to reflect this additional information. The authors wish to apologize for the omission.",
author = "Cullen, {K. R.} and P. Amatya and Roback, {M. G.} and Albott, {C. S.} and {Westlund Schreiner}, M. and Y. Ren and Eberly, {L. E.} and P. Carstedt and A. Samikoglu and M. Gunlicks-Stoessel and K. Reigstad and N. Horek and Tye, {Susannah J} and Lim, {K. O.} and B. Klimes-Dougan",
year = "2018",
month = "9",
day = "1",
doi = "10.1089/cap.2018.0030.correx",
language = "English (US)",
volume = "29",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Erratum

T2 - Intravenous ketamine for adolescents with treatment-resistant depression: An Open-Label Study, by Cullen KR, Amatya P, Roback MG, Albott CS, Westlund Schreiner M, Ren Y, Eberly LE, Carstedt P, Samikoglu A, Gunlicks-Stoessel M, Reigstad K, Horek N, Tye S, Lim KO, Klimes-Dougan B. (J Child Adolesc Psychopharmacol (2018) 28:7 (437-444) DOI: 10.1089/cap.2018.0030)

AU - Cullen, K. R.

AU - Amatya, P.

AU - Roback, M. G.

AU - Albott, C. S.

AU - Westlund Schreiner, M.

AU - Ren, Y.

AU - Eberly, L. E.

AU - Carstedt, P.

AU - Samikoglu, A.

AU - Gunlicks-Stoessel, M.

AU - Reigstad, K.

AU - Horek, N.

AU - Tye, Susannah J

AU - Lim, K. O.

AU - Klimes-Dougan, B.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - In the September 2018 issue of Journal of Child and Adolescent Psychopharmacology (vol. 28, no. 7, pp. 437-444), the article "Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study," by Dr. Kathryn R. Cullen et al., was missing the financial support information as follows: This research was supported by the National Institutes of Health's National Center for Advancing Translational Sciences (UL1TR002494), the Biotechnology Research Center (P41 EB015 894), the NINDS Institutional Center Core Grants to Support Neuroscience Research (P30 NS076408), the High Performance Connectome Upgrade for Human 3TMR Scanner (1S10OD017974-01), and the University Foundation, Amplatz Scholarship. The online version of the article has been corrected to reflect this additional information. The authors wish to apologize for the omission.

AB - In the September 2018 issue of Journal of Child and Adolescent Psychopharmacology (vol. 28, no. 7, pp. 437-444), the article "Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study," by Dr. Kathryn R. Cullen et al., was missing the financial support information as follows: This research was supported by the National Institutes of Health's National Center for Advancing Translational Sciences (UL1TR002494), the Biotechnology Research Center (P41 EB015 894), the NINDS Institutional Center Core Grants to Support Neuroscience Research (P30 NS076408), the High Performance Connectome Upgrade for Human 3TMR Scanner (1S10OD017974-01), and the University Foundation, Amplatz Scholarship. The online version of the article has been corrected to reflect this additional information. The authors wish to apologize for the omission.

UR - http://www.scopus.com/inward/record.url?scp=85060546962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060546962&partnerID=8YFLogxK

U2 - 10.1089/cap.2018.0030.correx

DO - 10.1089/cap.2018.0030.correx

M3 - Comment/debate

C2 - 30585735

AN - SCOPUS:85060546962

VL - 29

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 1

ER -